Accordingly, the European Association of the Study for Diabetes (EASD) and the American Diabetes Association (ADA), recommend SGLT2 inhibitors as the mainstay treatment of T2DM and the first line of T2DM treatment, in case of heart failure (HF) [7,8], and as an independent treatment of HF with a reduced ejection fraction, regardless of the diabetes status, according to the European Society of Cardiology (ESC) [9]. The gene discussed is SLC5A2; the disease is heart failure.